Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 16 years of above at the time of screening~* ability and willingness to provide written informed consent (or to obtain consent from parent guardian where applicable) and to comply with the schedule of protocol requirements~* Diagnosis of SLE according to ACR criteria. At least 4 criteria must have been present for the diagnosis of SLE. The 4 criteria do not have to be present at the time of screening~* Active lupus nephritis defined as follows: Biopsy proven (within 16 weeks prior to screening) ISN Class III or IV (A or A/C) not include III(C) IV(C) and VI (\>90% chronic irreversible scarring)~* Relapse or resistant to (3 consecutive doses) IVCY~* Resistant lupus or Relapse lupus nephritis defined as follows:~  * Increase in serum creatinine \>/= 0.3 mg/dl or~ * Increase in proteinuria \> 1.5 g/day (which must have improved by ≥ 50% in the preceding 3 months)~* Life-time cumulative dose of IVCY \> 6 grams~* Female patients of childbearing potential must have a negative serum pregnancy~Exclusion Criteria:~Relates to SLE~* Diagnosis of rapid progressive glomerulonephritis (RPGN): doubling serum creatinine and/or crescentic glomeruli ≥ 30%~* Severe renal impairment as defined by calculated creatinine clearance or MDRD-GFR \< 30 ml/min(except creatinine clearance or MDRD-GFR \> 50 ml/min in the 12 weeks prior to screening)~* History of serious disease or complication in any organ system that not appropriate to treatment immunosuppressive drug groups.~* Severe extra-renal organ involvement~Related to Treatment~* Previous of any Mycophenolate groups in the 6 months prior to screening~* Treatment with any investigational drugs in the 3 months prior to screening~Related to General Health~* Pregnancy or breast feeding mothers.~* Concomitant condition which has required treatment moderate to high dose steroid in the 12 weeks prior to screening.~* Evidence of significant uncontrolled concomitant disease in any organ system not related to SLE.~* History of cancer, including solid tumors, hematological malignancies and carcinoma.~* Evidence of current abuse of drugs or alcohol.~Related to Laboratory Findings~* Neutrophile \< 1,500/mm3, Hb \< 7g/L, Platelet \< 50,000/mm3 (except active SLE)~* Positive HBsAg or anti-HCV or anti-HIV.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral mycophenolate sodium 1440 mg per day for 12 months
- 2 (Type: ACTIVE_COMPARATOR): Intravenous cyclophosphamide monthly for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).